Dive into the AMP Trials

Results from the AMP Trials, studying a broadly neutralizing antibody (bNAb) known as VRC01, were complex, with still unfolding implications for the field.

The AMP Trials, two Phase IIb studies, tested the safety and efficacy of an infusion of VRC01 received every eight weeks. HVTN 703/HPTN 081 enrolled 1,900 women in sub-Saharan Africa, and HVTN 704/HPTN 085 enrolled 2,700 men who have sex with men and transgender people in North and South America and in Europe.

The overall efficacy demonstrated in the trials was not protective. But when VRC01 was fighting strains of HIV that were highly sensitive to it, the antibody did provide partial protection. So what does that mean for the field, and what other questions have been raised by these pioneering trials?

In this episode of Px Pulse, AVACers Jeanne Baron and Daisy Ouya talk to leading bNAb researcher, IAVI’s Devin Sok; a veteran HIV research advocate Mark Hubbard who served on AMP’s protocol team; and a senior member of the HVTN’s community engagement team, a chief explainer of the AMP trails, Gail Broder. Together we explore why these findings point to the need for combination antibodies, the need for a better understanding of the types of HIV that are circulating in a community, the complicated implications of a key lab test, the TZM-bl assay and more.

Hosted and produced by Jeanne Baron.

Highlights

• The HVTN’s Gail Broder explains the results of the AMP Trials (11:09)
• Researcher Devin Sok from IAVI and advocate Mark Hubbard on AMPs’ implications (12:57)

Resources

• Understanding Results of the AMP Trials — AVAC
• Results from AMP Trials — New England Journal of Medicine
• Dedicated webpage on antibody-mediated prevention studies, AVAC
• Efficacy Results Announced: Global first AMP trials, HPTN
• The AMP Trials — A Glass Half Full, New England Journal of Medicine
• The Future of Antibody-based HIV Prevention, IAVI Report
• AMP-ticipation: Context and concepts for understanding the AMP Trials, AVAC